Inhibikase Therapeutics Files 8-K Report

Ticker: IKT · Form: 8-K · Filed: Nov 20, 2025 · CIK: 1750149

Inhibikase Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyInhibikase Therapeutics, INC. (IKT)
Form Type8-K
Filed DateNov 20, 2025
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, administrative

TL;DR

Inhibikase Therapeutics filed an 8-K on Nov 20, 2025, updating its corporate address.

AI Summary

On November 20, 2025, Inhibikase Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 1000 N. West Street, Suite 1200, Wilmington, DE 19801. The report was filed under the 1934 Securities Exchange Act.

Why It Matters

This filing provides an official update on the company's administrative and reporting status with the SEC, which is important for investors to track regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine administrative update and does not contain new financial or operational information that would typically indicate significant risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information as required by the Securities Exchange Act of 1934, specifically noting the company's principal executive offices and filing date.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on November 20, 2025.

What is the official address of Inhibikase Therapeutics, Inc.'s principal executive offices?

The principal executive offices of Inhibikase Therapeutics, Inc. are located at 1000 N. West Street, Suite 1200, Wilmington, DE 19801.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is the SEC file number for Inhibikase Therapeutics, Inc.?

The SEC file number for Inhibikase Therapeutics, Inc. is 001-39676.

Filing Stats: 1,131 words · 5 min read · ~4 pages · Grade level 12.3 · Accepted 2025-11-20 16:11:46

Key Financial Figures

Filing Documents

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the potential effects of IKT-001, expectations regarding the Company's Phase 3 trial of IKT-001 in PAH, including design, timing of initiation and its impact on the Company's timeline; and the Company's future activities, or future events or conditions. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to commence and execute a Phase 3 trial to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Item9.01.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d)Exhibits. 99.1 Corporate Presentation of Inhibikase Therapeutics, Inc., dated November 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 20, 2025 INHIBIKASE THERAPEUTICS, INC. By: /s/ Mark Iwicki Mark Iwicki Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing